Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC?

Hepatology. 2024 Sep 1;80(3):E37-E38. doi: 10.1097/HEP.0000000000000803. Epub 2024 Feb 19.

Authors

Zheng Li¹, Yi Zhang¹, Ying Li², Xi Chen², Jie Hu³, Jiayun Yu², Yuzhu Hu¹, Shihong Nie², Nanjing Li², Qinglian Wen², Bingwen Zou¹

Affiliations

¹ Division of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
² Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
³ Department of Oncology, Sichuan Provincial Crops Hospital of Chinese People's Armed Police Forces, Leshan, China.

PMID: 38373119
DOI: 10.1097/HEP.0000000000000803

No abstract available

Publication types

Letter

MeSH terms

Antiviral Agents / therapeutic use
Carcinoma, Hepatocellular* / prevention & control
Hepatitis B, Chronic / complications
Hepatitis B, Chronic / drug therapy
Hepatitis B, Chronic / prevention & control
Humans
Liver Neoplasms* / prevention & control

Substances

Antiviral Agents